Sign In
Buy NKTR
$72.76
+2.17 (+3.07%)
At Close: Aug 04, 2026
– NKTR-0165 Demonstrates Selective Enhancement of Treg Cell Function Through Novel Agonistic Mechanism – – IND-Enabling Studies Underway for NKTR-0165 with First-in-Human Studies Planned in Firs
Nektar Management to Present at Upcoming Investor Conferences
06:00pm, Thursday, 30'th May 2024
SAN FRANCISCO , May 30, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) management is scheduled to present at upcoming investor conferences: Jefferies Healthcare Conference in New York City on
Nektar's (NKTR) Q1 Earnings and Revenues Surpass Estimates
12:35pm, Friday, 10'th May 2024
Nektar (NKTR) reports a narrower-than-expected loss in the first quarter of 2024 and tops revenue estimates.
Nektar Therapeutics, Inc. (NKTR) Q1 2024 Earnings Call Transcript
10:40pm, Thursday, 09'th May 2024
Nektar Therapeutics, Inc. (NASDAQ:NKTR ) Q1 2024 Earnings Conference Call May 9, 2024 5:00 PM ET Company Participants Vivian Wu - Associate Director, Investor Relations and Corporate Affairs Howard Ro
Nektar Therapeutics Reports First Quarter 2024 Financial Results
04:15pm, Thursday, 09'th May 2024
SAN FRANCISCO , May 9, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the first quarter ended March 31, 2024. Cash and investments in marketable securitie
Nektar to Announce Financial Results for the First Quarter 2024 on Thursday, May 9, 2024, After Close of U.S.-Based Financial Markets
06:00pm, Thursday, 02'nd May 2024
SAN FRANCISCO , May 2, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the first quarter 2024 on Thursday, May 9, 2024, after the close of U.S.-based fi
TEL AVIV, Israel and SAN FRANCISCO, April 24, 2024 (GLOBE NEWSWIRE) -- Biolojic Design, a biotechnology company that uses AI to transform antibodies into intelligent medicinal solutions, today announc
Nektar (NKTR) Up 7.5% Since Last Earnings Report: Can It Continue?
12:31pm, Wednesday, 03'rd Apr 2024
Nektar (NKTR) reported earnings 30 days ago. What's next for the stock?
Nektar Management to Present at the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference
02:00pm, Friday, 22'nd Mar 2024
SAN FRANCISCO , March 22, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) management is scheduled to present at the upcoming H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtua
Nektar (NKTR) Begins Phase IIb Study Rezpeg in Alopecia Areata
01:35pm, Wednesday, 06'th Mar 2024
The placebo-controlled, phase IIb study will investigate the efficacy and safety of Nektar's (NKTR) rezpeg in patients with severe to very severe alopecia areata.
Nektar (NKTR) Q4 Loss Wider Than Expected, Revenue Beat
11:11am, Tuesday, 05'th Mar 2024
Nektar (NKTR) reports a wider-than-expected loss in the fourth quarter of 2023 while revenue beat estimates.
SAN FRANCISCO , March 5, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR), a biotechnology company developing medicines for the treatment of auto-immune disorders, today announced the initiatio
Nektar Therapeutics (NKTR) Q4 2023 Earnings Call Transcript
10:54pm, Monday, 04'th Mar 2024
Nektar Therapeutics (NASDAQ:NKTR ) Q4 2023 Earnings Conference Call March 4, 2024 5:00 PM ET Company Participants Vivian Wu - Director, Investor Relations and Corporate Affairs Howard Robin - Presiden
Nektar Therapeutics (NKTR) Reports Q4 Loss, Tops Revenue Estimates
06:31pm, Monday, 04'th Mar 2024
Nektar Therapeutics (NKTR) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.20. This compares to loss of $0.32 per share a year ago.
Nektar Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results
04:15pm, Monday, 04'th Mar 2024
SAN FRANCISCO , March 4, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the fourth quarter and full year ended December 31, 2023. Cash and investments in
